Companies · Pharmaceuticals

Gelesis Holdings, Inc.

BOSTON · Pharmaceuticals

Diligence memoA one-page analyst read on Gelesis Holdings, Inc. — recommendation, valuation, rhythm, risks.
$576K
Total raised · real
1
Rounds
Latest step-up
Top 88%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Aug 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Gelesis Holdings, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 3.10× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
Dormant
  • Last raise 3.9 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Gelesis Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
3.9 yr record
Peak capital year was 2022 with $576K across 1 filings.
Market position
ahead of 13% of Pharmaceuticals peers
Capital scale is ahead of 13% of Pharmaceuticals peers; modeled value is above 14% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $576K across 1 filings.
  • Largest single filing was $576K on 2022-08-11.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Gelesis Holdings, Inc. is one of 1613 Pharmaceuticals companies tracked from BOSTON. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020
Year incorporated
2022-08-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2022-08-11 Raised $576K (real) Modeled valuation $7.9M (est)$576K$7.9MPre-Seed2022

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$576K · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$7.9M
Base estimate est.
$322K
Conservative case
$47.2M
Upside case
$3.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
3.9 yr
Elapsed time used
3.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
3.9 yr
On record since
2022
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$576K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.4× above median
This company$576K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.9M
Sector median$76.1M

Raised more than 13% of sector peers (real $). Modeled value above 14% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 38.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Eleison Pharmaceuticals Inc · Pre-Seed Raised $980K · modeled $15.9M (est)Telomir Pharmaceuticals, Inc. · Pre-Seed Raised $1.0M · modeled $9.7M (est)Drusolv Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $8.5M (est)TF Tech Ventures, Inc. · Pre-Seed Raised $625K · modeled $8.3M (est)Thyron Pharmaceuticals, Inc. · Pre-Seed Raised $500K · modeled $8.2M (est)MEDPhlow, LLC · Pre-Seed Raised $1.0M · modeled $6.6M (est)Centaur Bio Inc. · Pre-Seed Raised $1.5M · modeled $5.5M (est)7 Hills Pharma Inc. · Pre-Seed Raised $1.0M · modeled $4.9M (est)Artin Bioscience Inc. · Pre-Seed Raised $483K · modeled $4.8M (est)Precision Genetics, Inc. · Pre-Seed Raised $1.0M · modeled $4.8M (est)Zena Therapeutics Inc. · Pre-Seed Raised $500K · modeled $3.8M (est)Gelesis Holdings, Inc. (this company) Raised $576K · modeled $7.9M (est)Gelesis Holdings, Inc.
CompanyStageRaised · realValue · estvs peer med.
Eleison Pharmaceuticals IncPre-Seed$980K$15.9M6.25×
Telomir Pharmaceuticals, Inc.Pre-Seed$1.0M$9.7M3.81×
Drusolv Therapeutics, Inc.Pre-Seed$500K$8.5M3.33×
TF Tech Ventures, Inc.Pre-Seed$625K$8.3M3.25×
Thyron Pharmaceuticals, Inc.Pre-Seed$500K$8.2M3.23×
Gelesis Holdings, Inc. this companyPre-Seed$576K$7.9M3.10×
MEDPhlow, LLCPre-Seed$1.0M$6.6M2.57×
Centaur Bio Inc.Pre-Seed$1.5M$5.5M2.15×
7 Hills Pharma Inc.Pre-Seed$1.0M$4.9M1.94×
Artin Bioscience Inc.Pre-Seed$483K$4.8M1.88×
Precision Genetics, Inc.Pre-Seed$1.0M$4.8M1.87×
Zena Therapeutics Inc.Pre-Seed$500K$3.8M1.50×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$576K2022-08-11$3.2M$7.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$576K2022-08-11
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
Intelligence
Modeled next raise
$921K
Modeled next size est.range $599K$1.5M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Clayton L. Christopher1 other2022-08
David Pass1 other2022-08
Yishai Zohar1 other2022-08
Alessandro L. Sannino2022-08
Alison L. Bauerlein2022-08
David L. Abraham2022-08
Dominic L. Perks2022-08
Elaine L. Chiquette2022-08
Elliot L. Maltz2022-08
Harry L. Leider2022-08
Jane L. Wildman2022-08
Kathryn L. Cavanaugh2022-08
Paul L. Fonteyne2022-08
Raju L. Kucherlapati2022-08
Registry & provenance

Gelesis Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1805087
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lavior IncPharmaceuticalsPre-Seed$580K$13.3Msame sector · same stage
Goodsprout Co LLCPharmaceuticalsPre-Seed$600K$12.1Msame sector · same stage
NextEvo, Inc.PharmaceuticalsPre-Seed$600K$2.0Msame sector · same stage
Renavance Pharma, Inc.PharmaceuticalsPre-Seed$600K$4.7Msame sector · same stage
Pradama IncPharmaceuticalsPre-Seed$550K$14.2Msame sector · same stage
TIXiMED, Inc.PharmaceuticalsPre-Seed$550K$2.1Msame sector · same stage
Foment Bio, Inc.PharmaceuticalsPre-Seed$543K$2.6Msame sector · same stage
Oxygen Therapy, Inc.PharmaceuticalsPre-Seed$540K$14.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.1M85%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M84%
GelMEDIX, Inc.BiotechnologySeries A$1.6M83%
Enumeral Biomedical Holdings, Inc.PharmaceuticalsSeries B$22.7M83%
BiomX Inc.PharmaceuticalsSeries C$16.9M83%
Pharmazz, Inc.PharmaceuticalsSeries A$34.5M82%
RxBio Holdings, Inc.PharmaceuticalsSeries D+$12.0M82%
Cutispharma Holdings, Inc.PharmaceuticalsSeries C$2.5B82%
Frequently asked
How much funding has Gelesis Holdings, Inc. raised?
Gelesis Holdings, Inc. has raised approximately $576K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Gelesis Holdings, Inc.'s estimated valuation?
Provath's modeled valuation for Gelesis Holdings, Inc. is approximately $7.9M (modeled range $322K–$47.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Gelesis Holdings, Inc. at?
Gelesis Holdings, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Aug 11.
What does Gelesis Holdings, Inc. do and where is it based?
Gelesis Holdings, Inc. operates in the Pharmaceuticals sector, based in BOSTON.
Explore related

See where Gelesis Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Gelesis Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.